title: Addressing unmet needs in the treatment of COPD.
abstract: The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. francesco.patalano@novartis.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Patalano
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Donald
authors.initials: D
authors.lastname: Banerji
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: D'Andrea
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Fogel
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Pablo
authors.initials: P
authors.lastname: Altman
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Colthorpe
mesh_terms: D001249:Asthma / Q000175:diagnosis; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D001993:Bronchodilator Agents